Cogent Biosciences Announces Pricing of $200 Million Underwritten Public Offering

Strategic Insights -

Cogent Biosciences, a biotechnology company focused on developing precision therapies for genetically defined diseases, has announced the pricing of a $200 million underwritten public offering. The offering, which consists of 22,222,223 shares of common stock, is being sold by Cogent at a public offering price of $9.00 per share. The net proceeds from the offering will be used for continued development, regulatory, and commercial preparation activities related to bezuclastinib and other product candidates, as well as for working capital and general corporate purposes.

Key Takeaways:

  • Cogent Biosciences has priced a $200 million underwritten public offering, selling 22,222,223 shares of common stock at $9.00 per share.
  • The net proceeds from the offering will be used for continued development, regulatory, and commercial preparation activities related to bezuclastinib and other product candidates.
  • Cogent intends to use the net proceeds for working capital and general corporate purposes.
  • The company's most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation.
  • Cogent has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor.
  • The company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, and KRAS.
  • Cogent Biosciences is based in Waltham, MA, and Boulder, CO.

Statistics:

  • $200 million: The aggregate gross proceeds to Cogent from the offering.
  • 22,222,223: The number of shares of common stock being sold by Cogent.
  • $9.00: The public offering price per share.
  • 3,333,333: The number of additional shares of common stock that the underwriters have the option to purchase.
  • July 10, 2025: The expected closing date of the offering, subject to customary closing conditions.

Sources:

  • Press release, Cogent Biosciences, "Cogent Biosciences Announces Pricing of $200 Million Underwritten Public Offering," July 8, 2025.
  • Registration Statement on Form S-3ASR, filed by Cogent Biosciences with the Securities and Exchange Commission on February 10, 2023.
  • Preliminary prospectus supplement and accompanying base prospectus, filed by Cogent Biosciences with the Securities and Exchange Commission on July 8, 2025.